Aspirin could almost double GI cancer survival rate

A study conducted in the Netherlands analyzed nearly 1,400 GI cancer patients and found a subgroup of patients who took aspirin post-diagnosis had a higher survival rate than patients who did not, according to a Medscape report.

Patients in the group had various GI cancers including:

•    Colon cancer: 48 percent
•    Rectal cancer: 42.8 percent
•    Esophageal cancer: 10.2 percent

The subgroup of patients who took aspirin had a five-year survival rate of 75 percent, while the patients who did not take aspirin had a five-year survival rate of 40 percent.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast